Editing Openai/694257a5-9a50-8004-b15d-8af3ca7857db (section)

==== Original Investigation ====
* An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial<ref>{{cite web|title=An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial|url=https://chatgpt.com/share/An%20AI-Powered%20Lifestyle%20Intervention%20vs%20Human%20Coaching%20in%20the%20Diabetes%20Prevention%20Program:%20A%20Randomized%20Clinical%20Trial|publisher=An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial|access-date=2025-12-18}}</ref> 中文標題：糖尿病預防計畫：AI 生活型態介入 vs 人類教練的隨機試驗 類型：Original study（RCT；AI in Medicine） 導讀：RCT（n=724，前期糖尿病）：AI vs 人類教練。12 月複合達標 42.4% vs 41.4%，差 1.0%（95%CI −6.1～8.1）達非劣；活動量未非劣。 JAMA Network<ref>{{cite web|title=JAMA Network|url=https://jamanetwork.com/journals/jama/fullarticle/2840703|publisher=JAMA Network|access-date=2025-12-18}}</ref>
* Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score<ref>{{cite web|title=Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score|url=https://chatgpt.com/share/Development%20and%20Validation%20of%20the%20Sequential%20Organ%20Failure%20Assessment%20(SOFA|publisher=Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score|access-date=2025-12-18}}</ref>-2%20Score) 中文標題：SOFA-2 器官衰竭評分的開發與驗證 類型：Original study（預後/風險評分開發與驗證；Caring for the Critically Ill Patient） 導讀：330 萬成人 ICU 聯邦分析建模驗證；SOFA-2（0–24，納用藥/器官支持）院內死亡 AUROC 0.79 優於 SOFA 0.77，利於重症分層更新；GI/免疫未納入。 JAMA Network<ref>{{cite web|title=JAMA Network|url=https://jamanetwork.com/journals/jama/fullarticle/2840822|publisher=JAMA Network|access-date=2025-12-18}}</ref>
* Arsenic Exposure Reduction and Chronic Disease Mortality<ref>{{cite web|title=Arsenic Exposure Reduction and Chronic Disease Mortality|url=https://chatgpt.com/share/Arsenic%20Exposure%20Reduction%20and%20Chronic%20Disease%20Mortality|publisher=Arsenic Exposure Reduction and Chronic Disease Mortality|access-date=2025-12-18}}</ref> 中文標題：砷暴露下降與慢性病死亡率 類型：Original study（前瞻性隊列；環境健康） 導讀：前瞻隊列（10,977 人）追蹤至 2022：尿砷每 IQR↓197 μg/g，慢性病死亡 aHR 0.78；高→低於中位數 aHR 0.46，支持砷緩解與死亡下降相關。 PubMed<ref>{{cite web|title=PubMed|url=https://pubmed.ncbi.nlm.nih.gov/41247717/|publisher=pubmed.ncbi.nlm.nih.gov|access-date=2025-12-18}}</ref>